Related Experiment Videos
Syringotropic cutaneous T cell lymphoma treated with PUVA therapy
Alessandro Venturini1, Cristina Zane, Rosita Rodella
1Department of Dermatology, Spedali Civili, p.le Spedali Civili, 1 25123 Brescia, Italy. dermatologia@spedalicivili.brescia.it
European Journal of Dermatology : EJD
|July 29, 2005
Summary
Syringotropic cutaneous T cell Lymphoma (SCTCL), a rare skin cancer, presents unique histological features. This case study highlights PUVA therapy as a highly effective treatment for SCTCL.
Area of Science:
- Dermatology
- Oncology
- Pathology
Background:
- Syringotropic cutaneous T cell Lymphoma (SCTCL) is a rare, localized variant of cutaneous T cell lymphoma (CTCL).
- SCTCL is histopathologically defined by atypical T cell infiltrates around eccrine sweat glands, with minimal epidermotropism.
- The exact relationship between SCTCL and other CTCLs, such as mycosis fungoides, remains unclear.
Observation:
- This report details a patient presenting with classic clinical and histopathological signs of SCTCL.
- The patient exhibited erythematous papules characteristic of the condition.
Findings:
- The patient demonstrated an excellent therapeutic response to PUVA (psoralen plus ultraviolet A) therapy.
- This suggests PUVA therapy may be a viable and effective treatment option for SCTCL.
Implications:
- The findings suggest PUVA therapy could be a promising treatment for Syringotropic cutaneous T cell Lymphoma.
- Further research is warranted to establish PUVA therapy's efficacy and role in managing SCTCL.
- Clarifying the relationship between SCTCL and other CTCLs is crucial for improved diagnostic and therapeutic strategies.